Patents by Inventor Henry A. Erlich
Henry A. Erlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9914970Abstract: Disclosed is a method of determining KIR genotypes for one or more individuals in parallel, the method comprising: for each individual, amplifying the polymorphic exon sequences of the KIR genes, pooling the KIR amplicons, performing emulsion PCR followed by pyrosequencing in parallel to determine all the amplicon sequences present in the individual to determine which KIR alleles are present in the individual.Type: GrantFiled: February 3, 2015Date of Patent: March 13, 2018Assignees: Roche Molecular Systems, Inc., Conexio Genomics Pty Ltd, Children's Hospital & Research Center at OaklandInventors: Martha Ladner, Elizabeth Trachtenberg, Lloyd Gordon Bentley, Damian Goodridge, Henry A. Erlich
-
Publication number: 20150184243Abstract: Disclosed is a method of determining KIR genotypes for one or more individuals in parallel, the method comprising: for each individual, amplifying the polymorphic exon sequences of the KIR genes, pooling the KIR amplicons, performing emulsion PCR followed by pyrosequencing in parallel to determine all the amplicon sequences present in the individual to determine which KIR alleles are present in the individual.Type: ApplicationFiled: February 3, 2015Publication date: July 2, 2015Applicants: Roche Molecular Systems, Inc., Children's Hospital Oakland Research InstituteInventors: Martha Ladner, Elizabeth Trachtenberg, Lloyd Gordon Bentley, Damian Goodridge, Henry A. Erlich
-
Patent number: 9005894Abstract: Disclosed is a method of determining KIR genotypes for one or more individuals in parallel, the method comprising: for each individual, amplifying the polymorphic exon sequences of the KIR genes, pooling the KIR amplicons, performing emulsion PCR followed by pyrosequencing in parallel to determine all the amplicon sequences present in the individual to determine which KIR alleles are present in the individual.Type: GrantFiled: September 17, 2010Date of Patent: April 14, 2015Assignees: Roche Molecular Systems, Inc., Childrens Hospital & Research Center at Oakland, Conexio Genomics Pty LtdInventors: Martha Ladner, Elizabeth Trachtenberg, Lloyd Gordon Bentley, Damian Goodridge, Henry A. Erlich
-
Publication number: 20110129830Abstract: Disclosed is a method of determining KIR genotypes for one or more individuals in parallel, the method comprising: for each individual, amplifying the polymorphic exon sequences of the KIR genes, pooling the KIR amplicons, performing emulsion PCR followed by pyrosequencing in parallel to determine all the amplicon sequences present in the individual to determine which KIR alleles are present in the individual.Type: ApplicationFiled: September 17, 2010Publication date: June 2, 2011Applicant: ROCHE MOLECULAR SYSTEMS, INC.Inventors: Martha Ladner, Elizabeth Trachtenberg, Lloyd Gordon Bentley, Damian Goodridge, Henry A. Erlich
-
Publication number: 20100261189Abstract: A method for detecting one or more HLA sequence types is described that comprises the steps of: amplifying a plurality of first amplicons from a double stranded nucleic acid sample, wherein the first amplicons are amplified with a plurality of pairs of nucleic acid primers that define exons 2 and 3 of both strands of HLA loci from the group consisting of HLA-A, HLA-B, and HLA-C; amplifying the first amplicons to produce a plurality of populations of second amplicons, wherein each population of second amplicons is clonally amplified from one of the first amplicons; sequencing the plurality of populations of second amplicons to generate a nucleic acid sequence composition for each of the plurality of second amplicons; and detecting variation in the sequence composition from one or more of the second amplicons for one or more of the HLA loci.Type: ApplicationFiled: April 12, 2010Publication date: October 14, 2010Inventors: Gordon Bentley, Henry A. Erlich, Russell Gene Higuchi, Cherie Holcomb
-
Patent number: 7205106Abstract: The present invention provides methods and reagents for determining sequence variants present at the IL4 receptor, IL-4 and IL-13 loci, which facilitate identifying individuals at risk for type 1 diabetes.Type: GrantFiled: October 8, 2002Date of Patent: April 17, 2007Assignee: Roche Molecular Systems, Inc.Inventors: Daniel B. Mirel, Henry A. Erlich, Teodorica L. Bugawan, Janelle A. Noble, Ann Maria Valdes
-
Publication number: 20040126794Abstract: The present invention provides methods and reagents for detecting an individual's increased or decreased risk for type 1 diabetes, also known as, insulin dependent diabetes mellitus (“IDDM”).Type: ApplicationFiled: September 25, 2003Publication date: July 1, 2004Inventors: Teodorica L. Bugawan, Henry A. Erlich
-
Publication number: 20030152951Abstract: The present invention provides methods and reagents for determining sequence variants present at the IL4R locus, which facilitates identifying individuals at risk for type 1 diabetes.Type: ApplicationFiled: July 3, 2002Publication date: August 14, 2003Inventors: Daniel B. Mirel, Henry A. Erlich, Teodorica L. Bugawan, Janelle A. Noble, Ana Maria Valdez
-
Patent number: 6514736Abstract: The present invention is directed to a process for amplifying any target nucleic acid sequence contained in a nucleic acid or mixture thereof using a thermostable enzyme. The process comprises treating separate complementary strands of the nucleic acid with a molar excess of two oligonucleotide primers, extending the primers with a thermostable enzyme to form complementary primer extension products which act as templates for synthesizing the desired nucleic acid sequence, and detecting the sequence so amplified. The steps of the reaction can be repeated as often as desired and involve temperature cycling to effect hybridization, promotion of activity of the enzyme, and denaturation of the hybrids formed.Type: GrantFiled: November 1, 2000Date of Patent: February 4, 2003Assignee: Roche Molecular Systems, IncInventors: Henry A. Erlich, Glenn Horn, Randall K. Saiki, Kary B. Mullis, David H. Gelfand
-
Patent number: 6197563Abstract: The present invention is directed to a process for amplifying any target nucleic acid sequence contained in a nucleic acid or mixture thereof using a thermostable enzyme. The process comprises treating separate complementary strands of the nucleic acid with a molar excess of two oligonucleotide primers, extending the primers with a thermostable enzyme to form complementary primer extension products which act as templates for synthesizing the desired nucleic acid sequence, and detecting the sequence so amplified. The steps of the reaction can be repeated as often as desired and involve temperature cycling to effect hybridization, promotion of activity of the enzyme, and denaturation of the hybrids formed.Type: GrantFiled: November 18, 1994Date of Patent: March 6, 2001Assignee: Roche Molecular Systems, Inc.Inventors: Henry A. Erlich, Glenn Horn, Randall K. Saiki, Kary B. Mullis, David H. Gelfand
-
Patent number: 6194561Abstract: DNA sequences and corresponding amino acid sequences from the HLA class II beta region of the human genome that are associated with insulin-dependent diabetes mellitus (IDDM) and Pemphigus vulgaris (PV) have been identified. Specifically, marker DNA sequences which detect either directly or indirectly the identity of the codon encoding for the amino acid at position 57 of the DQ&bgr; protein sequence are disclosed as well as sequences from the DR&bgr; region. These sequences may be used to generate DNA hybridization probes and antibodies for assays to detect a person's susceptibility to autoimmune diseases, such as IDDM and PV. Such antibodies and peptides encoded by said DNA sequences can be used therapeutically or prophylactically.Type: GrantFiled: November 17, 1987Date of Patent: February 27, 2001Assignee: Roche Molecular Systems, Inc.Inventors: Henry A. Erlich, Glenn T. Horn
-
Patent number: 6040166Abstract: The present invention is directed to a process for amplifying any target nucleic acid sequence contained in a nucleic acid or mixture thereof using a thermostable enzyme. The process comprises treating separate complementary strands of the nucleic acid with a molar excess of two oligonucleotide primers, extending the primers with a thermostable enzyme to form complementary primer extension products which act as templates for synthesizing the desired nucleic acid sequence, and detecting the sequence so amplified. The steps of the reaction can be repeated as often as desired and involve temperature cycling to effect hybridization, promotion of activity of the enzyme, and denaturation of the hybrids formed.Type: GrantFiled: September 27, 1994Date of Patent: March 21, 2000Assignee: Roche Molecular Systems, Inc.Inventors: Henry A. Erlich, Glenn Horn, Randall K. Saiki, Kary B. Mullis, David H. Gelfand
-
Patent number: 5665548Abstract: DNA sequences and corresponding amino acid sequences from the HLA class II beta region of the human genome that are associated with insulin-dependent diabetes mellitus (IDDM) and Pemphigus vulgaris (PV) have been identified. Specifically, marker DNA sequences which detect either directly or indirectly the identity of the codon encoding for the amino acid at position 57 of the DQ.beta. protein sequence are disclosed as well as sequences from the DR.beta. region. These sequences may be used to generate DNA hybridization probes and antibodies for assays to detect a person's susceptibility to autoimmune diseases, such as IDDM and PV. Such antibodies and peptides encoded by said DNA sequences can be used therapeutically or prophylactically.Type: GrantFiled: May 23, 1995Date of Patent: September 9, 1997Assignee: Roche Molecular Systems, Inc.Inventors: Henry A. Erlich, Glenn T. Horn
-
Patent number: 5604099Abstract: Single or multiple nucleotide variations in nucleic acid sequence can be detected in nucleic acids by a process whereby the sample suspected of containing the relevant nucleic acid is repeatedly treated with primers, nucleotide triphosphates, and an agent for polymerization of the triphosphates and then denatured, in a process which amplifies the sequence containing the nucleotide variation if it is present. In one embodiment, the sample is spotted on a membrane and treated with a labeled sequence-specific oligonucleotide probe. Hybridization of the probe to the sample is detected by the label on the probe.Type: GrantFiled: June 1, 1995Date of Patent: February 18, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Henry A. Erlich, Glenn Horn, Randall K. Saiki, Kary B. Mullis
-
Patent number: 5567809Abstract: Primers for amplification of specific nucleic acid sequences of the second exon of HLA DRbeta genes and probes for identifying polymorphic sequences contained in the amplified DNA can be used in processes for typing homozygous or heterozygous samples from a variety of sources and for detecting allelic variants not distinguishable by serological methods. This HLA DRbeta DNA typing system can be used in a dot-blot format that is simple and rapid to perform, produces detectable signals in minutes, and can be used for tissue typing, determining individual identity, and identifying disease susceptible individuals.Type: GrantFiled: April 22, 1993Date of Patent: October 22, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Raymond J. Apple, Henry A. Erlich, Robert L. Griffith, Stephen J. Scharf
-
Patent number: 5541065Abstract: A process for determining the genotype of an individual with respect to the alleles at the HLA DP locus involves obtaining a sample of nucleic acid from the individual, and hybridizing the nucleic acids with a panel of probes specific for variant segments of DPalpha and DPbeta genes. Because the variation between DPbeta alleles is highly dispersed throughout the second exon of the DPbeta gene, the discovery of many different DPbeta alleles makes the process far more discriminating and informative than cellular, RFLP, or serological methods. The process can also be carried out on amplified nucleic acid produced by the polymerase chain reaction using primers specific for the second exon of the DPalpha and DPbeta genes. HLA DP DNA typing methods are useful in the prevention of graft rejection and host versus graft disease, in determining susceptibility to autoimmune diseases, in providing evidence concerning the derivation from an individual of forensic samples, and in paternity testing.Type: GrantFiled: February 14, 1994Date of Patent: July 30, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Henry A. Erlich, Glenn T. Horn, Teodorica Bugawan, Ann B. Begovich
-
Patent number: 5468613Abstract: Single or multiple nucleotide variations in nucleic acid sequence can be detected in nucleic acids by a process whereby the sample suspected of containing the relevant nucleic acid is repeatedly treated with primers, nucleotide triphosphates, and an agent for polymerization of the triphosphates and then denatured, in a process which amplifies the sequence containing the nucleotide variation if it is present. In one embodiment, the sample is spotted on a membrane and treated with a labeled sequence-specific oligonucleotide probe. Hybridization of the probe to the sample is detected by the label on the probe.Type: GrantFiled: March 9, 1990Date of Patent: November 21, 1995Assignee: Hoffmann-La Roche Inc.Inventors: Henry A. Erlich, Glenn Horn, Randall K. Saiki, Kary B. Mullis
-
Patent number: 5451512Abstract: Primers for amplification of specific nucleic acid sequences of the second and third exon of HLA Class I A gene and probes for identifying polymorphic sequences contained in the amplified DNA can be used in processes for typing homozygous or heterozygous samples from a variety of sources and for detecting allelic variants not distinguishable by serological methods. This HLA-A DNA typing system can be used in a forward or reverse dot-blot format that is simple and rapid to perform, produces detectable signals in minutes, and can be used for tissue typing, determining individual identity, and identifying disease susceptible individuals.Type: GrantFiled: September 28, 1993Date of Patent: September 19, 1995Assignee: Hoffmann-La Roche Inc.Inventors: Raymond J. Apple, Teodorica L. Bugawan, Henry A. Erlich
-
Patent number: 5386022Abstract: The presence or absence of a nucleic acid sequence associated with AIDS in a sample containing one or more nucleic acids and suspected of containing such sequence can be detected by amplifying the sequence using primers to form extension products as templates and detecting the amplified product if it is present. This may be accomplished by adding a labeled hybridization probe to the amplified product either free in solution or after immobilization on a solid support. Exemplary primers and probes for amplifying and detecting AIDS virus are provided.Type: GrantFiled: July 16, 1993Date of Patent: January 31, 1995Assignee: Hoffman-La Roche Inc.Inventors: John J. Sninsky, Shirley Y. Kwok, David Mack, Henry A. Erlich, Kary B. Mullis
-
Patent number: 5314809Abstract: Methods are provided for enhanced specificity and sensitivity of nucleic acid amplification. The methods are simplified nested amplification procedures wherein both inner and outer primer pairs are present in the amplification reaction mixture. According to the methods, the thermocycling profile, as well as the sequences, length, and concentration of amplification primers, is modified to regulate which primers are annealed and extended on the target during any particular amplification cycle. The methods described are particularly suitable in PCR amplifications and have numerous applications in molecular biology, medical diagnostics, and forensics.Type: GrantFiled: March 10, 1993Date of Patent: May 24, 1994Assignee: Hoffman-La Roche Inc.Inventors: Henry A. Erlich, Russell G. Higuchi